References
- Feghali-Bostwick C, Medsger Jr, TA, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003;48:1956–1963.
- Mayes MD, Reveille JD. Epidemiology, Demographics, and Genetics of Systemic Sclerosis. In: Clements PJ, editors. Systemic Sclerosis. 2003. In press.
- Fennell RFIJ, Rodnan GP, Vazquez H. Variability of tissue-localizing properties of serum from patients with different disease states. Lab Investig 1962;11:24–31.
- Beck JS, Anderson JR, Gray KG, Rowell NR. Antinuclear and precipitating autoantibodies in progressive systemic sclerosis. Lancet 1963;2:1188–1190.
- Douvas AS, Achten M, Tan EM. Identification of a nuclear protein (Sc1-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem 1979;254: 10514–10522.
- Shero JH, Bordwell B, Earnshaw WC. High titers of autoantibodies to topoisomerase I (SCL-70) in sera from scleroderma patients. Science 1986;14: 737–740.
- Maul GG, French BT, van Venrooij WJ, Jimenez SA. Topoisomerase I identified by scleroderma 70 antisera: Enrichment of topoisomerase I at the centromere in mouse mitotic cells before anaphase. Proc Natl Acad Sci 1986;83:5145–5149.
- Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C. Diversity of antinuclear antibodies in progressive systemic sclerosis: anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 1980;23:617–625.
- Reveille JD, Solomon DH. American college of Rheumatology, Ad Hoc Committee on immunologic testing guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Sc1-70 and nucleolar antibodies. Arthritis Rheum 2003;49: 399–412.
- Aeschlimann A, Meyer O, Bougeois P, Haim T, Belmatoug N, Palazzo E, Kahn MF. Anti-Sc1-70 antibodies detected by immunoblotting in progressive systemic sclerosis: specificity and clinical correlations. Ann Rheum Dis 1989;48:992-997. Hildebrandt S, Weiner E, Senecal JL, Noell S, Daniels L, Earnshaw WC, Rothfield NF. The IgG, IgM and IgA isotypes of antitopoisomerase-I and anticentromere autoantibodies. Arthritis Rheum 1990;33: 724–727.
- Tsay GJ, Fann RH, Hwang J. Specificity of anti-Sc1-70 antibodies in scleroderma: increased sensitivity of detection using purified DNA topoisomerase I from calf thymus. J Rheumatol 1990;17: 1314–1319.
- Cram DS, Fisicaro N, McNeilage LJ, Coopel RL, Harrison LC. Antibody specificities of Thai and Australian scleroderma sera with topoisomerase I recombinant fusion proteins. J Immunol 1993;151:6872 — 6881.
- Seelig HP, Schroter H, Ehrfeld H, Renz M. Autoantibodies against topoisomerase I detected with the natural enzyme and overlapping recombinant peptides. J Immunol Methods 1993;165:241-252, Oct. 15.
- Tan EM, Smolen JS, McDougal JS, Butcher BT, Conn D, Dawkins R, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, Rothfield NF, Smeenk R, Takasaki Y, Van Venrooij WJ, Wiik A, Wilson M, Koziol JA. A critical evaluation of enzyme immunoassays for detection of anti-nuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum 1999;42:455-464. Weiner ES, Earnshaw WC, Senecal JL, Bordwell B, Johnson P, Rothfield NF. Clinical associations of anticentromere anti-bodies and antibodies to topoisomerase I. Arthritis Rheum 1988;31: 378–385
- Clegg DO, Williams HJ, Singer JZ, Steen VD, Schlegel S, Ziminski C, Alarcon GS, Luggen ME, Polisson RP, Willkens RF, Yarboro C, McDuffie FC, Ward JR. Early undifferentiated connective tissue disease. II. The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases. J Rheumatol 1991;18:1340–1343.
- Catoggio LJ, Bernstein RM, Black CM, Hughes GRV, Maddison PJ. Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum D is 1983;42:23–27.
- Catoggio LJ, Skinner RP, Maddison PJ. Frequency and clinical significance of anticentromere and anti Sc1-70 antibodies in an English connective tissue disease population. Rheum Int 1983;3: 19–21.
- McNeilage LJ, Youngchaiyud U, Whittingham S. Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma. Arthritis Rheum 1989;32:54–60.
- Cruz M, Mejia G, Lavalle C, Cortes JJ, Reyes PA. Antinuclear antibodies in scleroderma, mixed connective tissue disease and primary Raynaud's phenomenon [published erratum appears in Clinphenomenon. Clin Rheum 1998;7:80-86, [published erratum appears in Chin Rheum Jun;7(2) (1998) 277].